Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.56 |
| ▸ | KDR | P35968 | 9/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33377880 | 0.80 | DGAT1 (0.53) | DGAT1KDRMKNK1PDE10ADYRK1A | |
| SCHEMBL234660 | 0.76 | DGAT1 (0.49) | DGAT1KDRMKNK1LRRK2 | |
| SCHEMBL16866775 | 0.76 | KDM4E (0.52) | DGAT1KDR | |
| SCHEMBL235971 | 0.76 | DGAT1 (0.53) | DGAT1KDRMKNK1 | |
| SCHEMBL1759113 | 0.74 | KDM4E (0.48) | DGAT1KDR | |
| SCHEMBL12647972 | 0.73 | DGAT1 (0.48) | DGAT1KDR | |
| SCHEMBL2755258 | 0.71 | ALDH1A1 (0.46) | DGAT1KDR | |
| SCHEMBL2755165 | 0.70 | ALDH1A1 (0.45) | DGAT1KDR | |
| SCHEMBL12647975 | 0.70 | DGAT1 (0.43) | DGAT1KDR | |
| SCHEMBL12663993 | 0.70 | DGAT1 (0.55) | DGAT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0847271-B1 | PYRAZOLO-(1,5-a)-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND HAIR DYES CONTAINING THESE | OREAL (FR) | 2002-05-02 | — | — | EP | claimed |
| JP-3016599-B2 | — | — | 2000-03-06 | — | — | JP | claimed |
| EP-0847271-A1 | PYRAZOLO-(1,5-a)-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND HAIR DYES CONTAINING THESE | L'OREAL (FR) | 1998-06-17 | — | — | EP | claimed |
| WO-1997049378-A1 | PYRAZOLO-(1,5-a)-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND HAIR DYES CONTAINING THESE | L'OREAL (FR) | 1997-12-31 | — | — | WO | claimed |
| EP-2406250-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8614221-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| EP-0847271-B1 | PYRAZOLO-(1,5-a)-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND HAIR DYES CONTAINING THESE | OREAL (FR) | 2002-05-02 | — | — | EP | disclosed |
| US-6099593-A | (DI)AMINO-SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AS OXIDATION BASE; PRODUCE INTENSE COLORATIONS AND WHICH HAVE GOOD RESISTANCE TO EXTERNAL AGENTS SUCH AS LIGHT, WEATHER, WASHING, ARE READILY SYNTHESIZABLE AND ARE CHEMICALLY STABLE | L'OREAL (FR) | 2000-08-08 | — | — | US | disclosed |
| US-6077320-A | DYEING HAIR WITHOUT AN OXIDIZER BY REACTION OF HAIR DYE WITH A PRIMARY OR SECONDARY AMINE-FUNCTIONAL COMPOUND IN THE DYE MEDIUM | L'OREAL (FR) | 2000-06-20 | — | — | US | disclosed |
| EP-0847749-B1 | Use of diiminoisoindoline or 3-aminoisoindolone derivatives for the dyeing of keratinic fibers and compositions containing them | OREAL (FR) | 1999-12-01 | — | — | EP | disclosed |
| EP-0847749-A1 | Use of diiminoisoindoline or 3-aminoisoindolone derivatives for the dyeing of keratinic fibers and compositions containing them | L'OREAL (FR) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3R5 | DGAT1 2268/4885KDR 2067/4885MKNK1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.